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vs. MPT via MP showed a statistically not significant advantage for VMP regarding 
survival outcomes. Significant benefits were observed for CR and development of 
any grade 3-4 AEs favouring VMP. ConClusions: Analysis of both aggregated and 
individual patient data essentially lead to the same conclusions, i.e. VMP and MPT 
seem more effective than MP, VMP seems ahead of MPT regarding response criteria 
and adverse events. We found significant between-trials heterogeneity, however 
no consistent relationship of effect and study-level covariates (e.g. maintenance 
dosing) was apparent. Thus, we relied on the random effects approach to meta-
analysis to cope with the unexplained trial-to-trial variability. Our results may best 
be confirmed by a head-to-head trial of VMP vs. MPT.
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objeCtives: A health technology assessment (HTA) informing the recent NICE 
guidance regarding the use of erythropoiesis-stimulating agents (ESA) in cancer-
treatment induced anaemia (CIA) identified uncertainty around the overall survival 
hazard ratio (OSHR). We investigated how the understanding of OS in CIA patients 
treated with ESAs has shaped over time and the effects of accumulating OS evidence 
on cost-effectiveness. In addition, the effects of narrowing inclusion criteria, by com-
paring the HTA results to a recent Cochrane review, were investigated. Methods: 
CMA was applied to both HTA review and Cochrane review OS data to identify pat-
terns in results; study results were accumulated by the year of publication. Annual 
OSHR results from the CMA were applied to an economic model developed in the 
HTA to calculate the cost-effectiveness of ESAs. Results: Precision of the OSHR 
estimate appeared to improve with additional evidence, but the true location of the 
estimate remained uncertain and the best estimate varied over time. Using the HTA 
CMA, results from 2001 and 2002 suggested survival benefits to using ESAs (0.77, 95% 
CI 0.60–0.98 and 0.78, 95% CI 0.65–0.93 respectively), with ESAs being cost-effective 
at a willingness to pay threshold of £30,000 per QALY for all values of the OSHR 95% 
CI. HTA CMA for all other years and all Cochrane CMA results did not suggest any 
significant effects of ESAs on OS. Cost-effectiveness results were therefore uncer-
tain. ConClusions: Current evidence suggests we cannot reject the possibility 
of no difference in OS between patients receiving or not receiving ESAs, regardless 
of study inclusion criteria. However, there is also insufficient evidence to support 
such conclusions, particularly as earlier results from narrower inclusion criteria sug-
gested some survival benefits. This analysis highlights the additional uncertainty of 
the current evidence base on cost-effectiveness analyses, which cannot be captured 
in standard sensitivity analyses.
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objeCtives: The question of sequencing multiple myeloma (MM) treatments is a 
key one, as is the retreatment in patients where the same treatment was effective 
in earlier lines. We investigated bortezomib retreatment in a Swedish MM national 
registry. Methods: Patients diagnosed with MM since January 2000 until June 2011 
from 7 university clinics, 5 regional centers and 3 local hospitals in Sweden were 
included. Time to response and overall survival (OS) were analyzed using stratified 
Kaplan-Meier analysis. Results: Of the 541 patients treated with bortezomib (out 
of a total population of n= 1638), 93 were retreated with bortezomib. Median follow-
up from start of retreatment was 10.2 mos. Median age was 63.5 (range 38–83), 57.3% 
were male, 34.2%/15.9%/20.7% had stage I/II/III disease (ISS); median number of 
prior therapies at initial bortezomib and retreatment was 1 and 3. 26.8%/32.9% of 
pts initiated retreatment as 3rd/4th line therapy. 37.8%/22.0% initiated bortezomib 
retreatment in combination with dexamethasone, 7.3% in monotherapy, compared 
to 40.3%, 21.8% and 8.5%, at initial bortezomib. ≥ PR/VGPR-rates at re-treatment were 
59.1%/12.7%, compared to 82.0%/39.9% at initial bortezomib. Median time to ≥ PR/
VGPR was 2.4/1.3 months at retreatment versus 1.9/2.1 at initial bortezomib. The 
≥ PR rate at retreatment was numerically longer in patients with < = 2 (75.1%) vs > = 3 
(20%) therapies prior to retreatment. Median PFS/OS from start of re-treatment was 
5.5 [95%CI: 3.7, 10.0]/17.4 [10.3, 26] months, compared to 8.1 [6.9, 9.7]/25.9 months 
[21.0, 31.6] for initial bortezomib. Number of prior therapies at retreatment did not 
affect PFS; however, OS was longer in pts with fewer prior therapies (p= 0.0112). 
There was a trend towards longer PFS (p= 0.087) in retreated patients who achieved 
> = PR compared to non-responders. ConClusions: These data suggest that, in 
everyday medical practice, bortezomib retreatment is effective in relapsed/refrac-
tory MM, with more than half of pts who responded to initial bortezomib achieving 
≥ PR at retreatment.
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objeCtives: The aim was at assembling published evidence on treatments for RAS 
wild-type (wt) (KRAS and NRAS exon 2,3,4) metastatic colorectal cancer (mCRC) 
to evaluate the efficacy and safety of cetuximab in combination with FOLFOX or 
FOLFIRI chemotherapy as first line treatment of these patients. The outcomes of 
interest were progression free survival (PFS), overall survival (OS), overall response 
(ORR), and adverse event data. Methods: A systematic literature search was per-
formed on the 24th March 2014 in Medline, Embase, and The Cochrane Library to 
identify all randomized controlled trials (RCTs) as well as single arm trials concern-
ing the efficacy and safety of first line interventions of interest in patients with 
RAS wt mCRC. Abstract and article selection was performed by two independent 
researchers, with a third person resolving disagreements, according to predefined 
standards, which were based on criteria for patient, intervention, comparator, 
outcomes and study design (PICOS). Results: 596 citations were identified after 
removing duplicates. 520 citations were excluded for reasons including: patient 
population (231), study design (174), intervention (74), outcomes (23) and duplicates 
(18). A total of 76 abstracts were included and the full-text version of these publica-
tions were retrieved and screened resulting in excluding 69 further publications due 
to the study design (20), patient population (43), outcomes (5), and one (1) duplicate, 
not being in line with the review selection criteria. Ten citations on five different 
RCTs were identified that met the inclusion criteria. ConClusions: This system-
atic review provided the latest studies on RAS wild-type (wt) metastatic colorectal 
cancer (mCRC) treatments. Despite the small number of studies available for a 
relatively new biomarker-specific mCRC, anti- EGFR treatments such as cetuximab 
in combination with FOLFOX and FOLFIRI have demonstrated a significant benefit 
in progression free survival (PFS), overall survival (OS) and overall response rate 
(ORR) versus chemotherapy alone in mCRC RAS wt patients.
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objeCtives: Malignant pleural mesothelioma (MPM) is a rare tumour with a poor 
survival and prognosis. In Russia, the epidemiology of this disease has not been well 
studied. We conducted an epidemiological study to understand the characteristics of 
patients with MPM in Russia. Methods: Retrospective study of the characteristics 
of patients with MPM. Patients treated for 1st and 2ndline therapy were included 
in ten centers of the Russian Federation. The data were generated from hospital 
records, electronic databases, and other sources of information between June and 
December in 2013. Results: One hundred and twelve patients were enrolled. The 
average age was 60.0±10.87 years and 42% were women. Harmful work environ-
ment was indicated in 21/112 (18.8%) of the patients. The exposure to asbestos was 
reported in 10/112 (8.9%) patients, and contact with erionite in 8/112 (7.1%) patients. 
Fifty percent (56/112) of the patients were smokers or are current smokers; smoking 
period was 25.3±13.25 years. The disease stage at diagnosis was I-II in 31 (27.6%), 
III-IV in 81 (72.4 %) patients. The ECOG performance status was 0 in 16 (14.3%), 
1 in 46 (41.1%), 2 in 30 (26.8%), 3 in 15 (13.4%) and 4 in 1 (0.9%) patients, in 4 patients 
- unknown. 50/112 (44.6%) patients had immunohistochemical verification of the 
diagnosis. Antineoplastic drugs were used to treat 85/112 (75.9%) patients. The main 
drugs used were cisplatin (n= 75), gemcitabine (32), doxorubicin (34), pemetrexed 
(29) and carboplatin (21). ConClusions: In Russia, the majority of MPM patients 
were diagnosed at advanced stages of disease. In 80% of the cases, a harmful work 
environment was not identified. Given the low prevalence and the frequent use 
of off-label medicines, it can be considered an orphan disease. Limitations: Only 
limited number of centres was included.
PCN21
first-liNe theraPy for PatieNts With multiPle myeloma: direCt aNd 
iNdireCt ComParisoN of treatmeNt regimeNs oN the existiNg market
Kuhr K.1, Wirth D.2, Srivastava K.3, Lehmacher W.1, Hellmich M.1
1University of Cologne, Cologne, Germany, 2Janssen-Cilag, Neuss, Germany, 3Heron India, 
Chandigarh, India
objeCtives: Motivated by the discussion whether the german AMNOG is applied 
to currently marketed drugs we compared first-line therapies for patients with 
multiple myeloma (MM). Methods: A systematic literature search for randomized 
controlled trials (RCTs) was conducted and VMP (bortezomib (Velcade), melphalan 
and prednisone), MPT (melphalan, prednisone and thalidomide) and MP (melpha-
lan and prednisone) were identified as therapies of interest. We extracted infor-
mation on overall survival (OS), progression-free survival (PFS), response criteria 
(CR, VGPR, PR), and grade 3-4 AEs (any, hematological, non-hematological, DVT, 
PNP). Random-effects meta-analysis was used for direct and the Bucher method 
for adjusted indirect treatment comparison. Results: Seven RCTs with a total of 
2,367 patients were included in our analyses, one RCT (n= 682) comparing VMP vs. 
MP and six RCTs (n= 1,685) comparing MPT vs. MP. Direct head-to-head comparison 
of  VMP vs. MPT was lacking. For MPT vs. MP, data were extracted from a recently 
published meta-analysis of individual patient data if available. VMP was superior to 
MP regarding OS. Both VMP and MPT were superior to MP regarding PFS and response 
criteria, but had a higher risk of developing AEs. The indirect comparison of VMP 
